| Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid (NCT05366127) | University Hospital, Rouen | 2022-07-01 |
| A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (NCT05267600) | argenx | 2022-06-09 |
| Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) (NCT05061771) | AKARI Therapeutics | 2022-05-06 |
| Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid (NCT06479018) | CHU de Reims | 2022-02-10 |
| JAK Inhibitors' Efficacy in Bullous Pemphigoid (NCT06561256) | Chao Ji | 2022-01-01 |
| Telederm and Bullous Pemphigoid (NCT04728854) | Emory University | 2021-03-15 |
| Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid (NCT03926377) | Centre Hospitalier Universitaire, Amiens | 2020-12-11 |
| A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid (NCT04206553) | Regeneron Pharmaceuticals | 2020-10-28 |
| Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (NCT04563923) | Centre Hospitalier Universitaire de Nice | 2020-10-10 |
| Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy (NCT04641884) | Nantes University Hospital | 2020-04-01 |
| Efficacy and Safety of Ustekinumab in Bullous Pemphigoid (NCT04117932) | CHU de Reims | 2020-03-11 |
| Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? (NCT03636763) | Assistance Publique Hopitaux De Marseille | 2018-09-01 |
| Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid (NCT03272958) | University Hospital, Brest | 2017-11-07 |
| A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid (NCT03286582) | TWi Biotechnology, Inc. | 2017-09-05 |
| Ixekizumab in the Treatment of Bullous Pemphigoid (NCT03099538) | Mayo Clinic | 2017-08-15 |
| Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population (NCT05284929) | Sechenov University | 2017-05-17 |
| Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid (NCT04128176) | University of California, Davis | 2017-03-01 |
| Autoimmune Blistering Diseases Study (NCT02753777) | University of Pennsylvania | 2016-04-01 |
| Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid (NCT02360202) | University Hospital, Rouen | 2015-02-17 |
| Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients (NCT03320798) | CHU de Reims | 2013-10-01 |
| Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid (NCT02837965) | CHU de Reims | 2013-09-26 |
| Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (NCT01688882) | Novartis Pharmaceuticals | 2013-01-01 |
| Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid (NCT01571895) | Dompé Farmaceutici S.p.A | 2012-02-20 |
| Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids (NCT01408550) | Nihon Pharmaceutical Co., Ltd | 2011-08-01 |
| Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission (NCT01265082) | National Taiwan University Hospital | 2010-12-01 |
| Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid (NCT02883894) | CHU de Reims | 2009-11-01 |
| The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors (NCT04469582) | University of Athens | 2009-04-01 |
| Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (NCT00525616) | University Hospital, Rouen | 2008-12-01 |
| Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid (NCT02313870) | University Hospital, Montpellier | 2008-01-22 |
| Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid (NCT00802243) | University Hospital, Limoges | 2007-09-01 |
| Efficacy and Safety of Omalizumab in Bullous Pemphigoid (NCT00472030) | University of Iowa | 2007-08-01 |
| Rituximab in the Treatment of Patients With Bullous Pemphigoid (NCT00286325) | Duke University | 2005-03-01 |
| Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus (NCT00213421) | University Hospital, Rouen | 2001-08-01 |
| Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid (NCT05906706) | Regeneron Pharmaceuticals | |